D-W Kim has received clinical trial research funding to his institution from Alpha Biopharma, Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi Sankyo, GSK, Hanmi Pharmaceutical, InnoN, IQVIA, Janssen, Merck, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, and Yuhan; and received support for medical writing assistance from Amgen, AstraZeneca, Boehringer Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi Sankyo, GSK, Janssen, Merus, Mirati Therapeutics, MSD, Merck, Novartis, Pfizer, Roche, Takeda, and Yuhan. AM Schram has served on advisory boards for Relay Therapeutics, Mersana, and Merus; consulted for Blueprint Bio and Flagship Pioneering; served on steering committees for Merus and Pfizer; received research funding (paid to the institution) from AstraZeneca, ArQule, BeiGene/Springworks, Black Diamond Therapeutics, Elevation Oncology, Kura, Lilly, Merus, Northern Biologics, Pfizer, PMV Pharma, Relay, Repare Therapeutics, Revolution Medicine, and Surface Oncology; received food and beverage from PUMA and Repare Therapeutics; and acknowledges ASCO Conquer Cancer Foundation CDA, NCI P30CA008748 CCITLA, Cycle for Survival, Memorial Sloan Kettering Cancer Center Support Grant (P30 CA008748). A Hollebecque has financial interests (personal; invited speaker) in Servier, Incyte, and EISAI; financial interests (personal; advisory board) in Basilea, Tahio, Relay Therapeutics, QED Therapeutics, Debiopharm, MSD, and Boehringer Ingelheim; financial interests (institutional; funding) in Incyte; financial interests (institutional; research grant) in AstraZeneca; non-financial interests as the principal investigator of M19-345 for AbbVie; non-financial interests as the principal investigator of CO42216, WP42627, and CO40939 for Roche; non-financial interests as the principal investigator of MCLA-158 for Merus; non-financial interests as the principal investigator of SGNB6A for Seagen; non-financial interests as the principal investigator of TAS-120-202 for Tahio; non-financial interests as the principal investigator of Krystal-10 for Mirati; non-financial interests as the principal investigator of ADP-0033 for Adaptimmune; non-financial interests as the principal investigator of ACT16902 for Sanofi; non-financial interests as the principal investigator of C4201002 for Pfizer; non-financial interests as the principal investigator of RLY-4008 for Relay Therapeutics; non-financial interests as the principal investigator of CC-90011 for Celgene/BMS; non-financial interests as the principal investigator of Loxo-IDH for Loxo/Lilly; non-financial interests as the principal investigator of a trial for AstraZeneca; non-financial interests as the principal investigator of the SN-201 study for Sotio; non-financial interests as the principal investigator of Tropics-03 for Gilead; and non-financial interests as the principal investigator of BI1403 for Boehringer Ingelheim. K Nishino has received research support from Merus, AstraZeneca, Eli Lilly, Pfizer, Daiichi Sankyo, AbbVie, Taiho, Bayer, Takeda, ONO Pharmaceutical, Amgen, Eisai, Sanofi, Janssen, Novartis, Merck, Chugai, and MSD; and received personal fees (honoraria) from AstraZeneca, Eli Lilly Japan, Pfizer, Novartis, Merck, BMS, Chugai, Janssen, Roche Diagnostics, Nippon Kayaku, Nippon, and Boehringer Ingelheim. T Macarulla has served as a consultant or advisor for Amgen, Servier, Incyte, Sanofi, AstraZeneca, Taiho, Celgene, Boehringer Ingelheim, and Eisai; received research funding from Celgene, AstraZeneca, BeiGene, Incyte, and Loxo; and served as a speaker for AstraZeneca, Incyte, Servier Roche, and Eisai. SY Rha has nothing to disclose. M Duruisseaux has served as a member of an advisory council or committee for BMS, GSK, Sanofi, MSD, AstraZeneca, AbbVie, Takeda, Boehringer Ingelheim, Amgen, Guardant Health, and Pfizer; received consulting fees from Roche, BMS, MSD, AstraZeneca, AbbVie, Takeda, Boehringer Ingelheim, GamaMabs Pharma, and Pfizer; and received grants from Takeda, NanoString, Eli Lilly, and Blueprint Medicines. SV Liu serves as a paid consultant or advisor to AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, Regeneron, Sanofi, Takeda, and Turning Point Therapeutics; and has received research grants (paid to institution) from Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, and Turning Point Therapeutics. M Najeeb Al Hallak has served on speakers bureaus for IPSEN, AstraZeneca, Guardant Health, and Seagen; received a $354,000 U-Cancer VIVE grant to support a pancreatic cancer translational clinical trial in 2022; is a coinvestigator on 2 National Cancer Institute grants, each supporting 10% of his Wayne State University (WSU) salary (R37 MERIT Award R37CA215427-01A1 and 1R01CA240607-01A1); has helped on a multiple principal investigator grant to secure a fund of $60,000 to support preclinical research at Dr Azmi's lab from a pharmaceutical company (Purple Biotech); is a coinvestigator on Michigan State University (MSU), 22-1056, and US Department of Defense, 22-1428, grants, each supports 5% of his WSU salary; is a coinvestigator on the nuclear imaging grant sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, 22-0865, which supports 5% of his WSU salary; and is a coinvestigator on the SPORE project, 22-0276, in collaboration with the University of Alabama–Birmingham, which will support 10% of his salary. K Umemoto has received honoraria from Taiho Pharmaceutical and Chugai Pharmaceutical. C Wesseler has received honoraria from BMS, Roche, Lilly, AstraZeneca, Takeda, Novartis, GSK, MSD, Boehringer Ingelheim, and Novocure. JM Cleary receives research funding to his institution from Merus, Roche, Servier, and BMS; receives research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences, and Apexigen; has received honoraria for participating in advisory boards of Incyte and Blueprint Medicines; and has given educational talks sponsored by Bayer, Merck, AstraZeneca, and Genentech. C Springfeld has received honoraria for advisory boards or lectures from AstraZeneca, Bayer, Eisai, Incyte, MSD, Roche, Servier, and Taiho. C Neuzillet has received honoraria and consulted for Amgen, AstraZeneca, Baxter, Bristol Myers Squibb, Fresenius Kabi, Incyte Biosciences, Merck, MSD, Mundipharma, Novartis, Nutricia, OSE Immunotherapeutics, Pierre Fabre, Roche, Sanofi, Servier, and Viatris; and received research funding for clinical trials from AstraZeneca, Bristol Myers Squibb, Fresenius Kabi, Nutricia, OSE Immunotherapeutics, Roche, Servier, and Viatris. A Joe, S Jauhari, and J Ford are employees of Merus. K Goto has received research funding (paid to institution) from Merus NV, Amgen Inc., Amgen K.K., Amgen Astellas BioPharma K.K., Bayer Yakuhin Ltd, Boehringer Ingelheim Japan Inc., Bristol Myers Squibb K.K., Blueprint Medicines Corporation, Craif Inc., Daiichi Sankyo Co. Ltd, Eisai Co. Ltd, Eli Lilly Japan K.K., Haihe Biopharma Co. Ltd, Ignyta Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co. Ltd, Kyowa Kirin Co. Ltd, Life Technologies Japan Ltd, Loxo Oncology Inc., LSI Medicine Corporation, Medical & Biological Laboratories Co. Ltd, Merck Biopharma Co. Ltd, MSD K.K., Novartis Pharma K.K., ONO Pharmaceutical Co. Ltd, Pfizer Japan Inc., Pfizer R&D Japan G.K., Precision Medicine Asia Co. Ltd, Riken Genesis Co. Ltd, Sumitomo Pharma Co. Ltd, Spectrum Pharmaceuticals Inc., Sysmex Corporation, Taiho Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, Turning Point Therapeutics Inc., and Xcoo Inc.; received honoraria from Amgen Inc., Amgen K.K., Amoy Diagnostics Co. Ltd, AstraZeneca K.K., Bayer Healthcare Pharmaceuticals Inc., Bayer Yakuhin Ltd, Boehringer Ingelheim Japan Inc., Blueprint Medicines Corporation, Daiichi Sankyo Co. Ltd, Eisai Co. Ltd, Eli Lilly Japan K.K., Guardant Health Inc., Haihe Biopharma Co. Ltd, Janssen Pharmaceutical K.K., Medpace Japan K.K., Merck Biopharma Co. Ltd, Nippon Kayaku Co. Ltd, Novartis Pharma K.K., ONO Pharmaceutical Co. Ltd, Otsuka Pharmaceutical Co. Ltd, Riken Genesis Co. Ltd, Taiho Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co. Ltd; and served on a data safety monitoring board or advisory board for Amgen Inc., Amgen K.K., Daiichi Sankyo Co. Ltd, and Eli Lilly Japan K.K. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.